Quantitative modeling of chronic myeloid leukemia: Insights from radiobiology

Blood

Volumn 119, Issue 19, 2012, Pages 4363-4371

  Radivoyevitch, Tomas ^a   Hlatky, Lynn ^b   Landaw, Julian ^c   Sachs, Rainer K ^b,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ATOMIC BOMB; CANCER STEM CELL; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; DOSIMETRY; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VIVO STUDY; IONIZING RADIATION; LATENT PERIOD; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL; RADIOBIOLOGY; REVIEW;

EID: 84860912925     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-381855     Document Type: Review

References (100)

1. Cortes J, Deininger M. Chronic Myeloid Leukemia. New York, NY: informa; 2007.
2. Carella A, Daley G, Eaves C, Goldman J, Hehlmann R. Chronic Myeloid Leukaemia: Biology and Treatment. London, United Kingdom: Martin Dunitz; 2001.
3. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-566.
4. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11): 994-1004. (Pubitemid 36302244)
5. Kantarjian HM, Cortes J, La Rosee P, Hochhaus A. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer. 2011;116(6):1419-1430.
6. Hehlmann R, Jung-Munkwitz S, Saussele S. Treatment of chronic myeloid leukemia when imatinib fails. Expert Opin Pharmacother. 2011;12(2): 269-283.
7. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2011;11(11):1029-1035.
8. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619-1630.
9. Whichard ZL, Sarkar CA, Kimmel M, Corey SJ. Hematopoiesis and its disorders: a systems biology approach. Blood. 2010;115(12):2339-2347.
10. Hehlmann R, Saussele S. Treatment of chronic myeloid leukemia in blast crisis. Haematologica. 2008;93(12):1765-1769.
11. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441-453. (Pubitemid 46823444)
12. Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid leukemia. Leukemia. 2010;24(11):1823-1833.
13. Rubinow SL, Lebowitz JL. A mathematical model of neutrophil production and control in normal man. J Math Biol. 1975;1:187-225.
14. Fokas AS, Keller JB, Clarkson BD. Mathematical model of granulocytopoiesis and chronic myelogenous leukemia. Cancer Res. 1991;51(8):2084-2091.
15. Tang M, Gonen M, Quintas-Cardama A, et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011; 118(6):1622-1631.
16. Leder K, Foo J, Skaggs B, Gorre M, Sawyers CL, Michor F. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of preexisting resistance in chronic myeloid leukemia. PLoS One. 2011;6(11):e27682.
17. Lenaerts T, Pacheco JM, Traulsen A, Dingli D. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica. 2010;95(6):900-907.
18. Horn M, Loeffler M, Roeder I. Mathematical modeling of genesis and treatment of chronic myeloid leukemia. Cells Tissues Organs. 2008;188(1-2): 236-247. (Pubitemid 351962246)
19. Kim PS, Lee PP, Levy D. Modeling imatinibtreated chronic myelogenous leukemia: reducing the complexity of agent-based models. Bull Math Biol. 2008;70(3):728-744.
20. Paquin D, Kim PS, Lee PP, Levy D. Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia. Bull Math Biol. 2011;73(5):1082-1100.
21. Roeder I, d'Inverno M. New experimental and theoretical investigations of hematopoietic stem cells and chronic myeloid leukemia. Blood Cells Mol Dis. 2009;43(1):88-97.
22. Sachs RK, Johnsson K, Hahnfeldt P, Luo J, Chen A, Hlatky L. A multicellular basis for the origination of blast crisis in chronic myeloid leukemia. Cancer Res. 2011;71(8):2838-2847.
23. Gilbert ES. Ionising radiation and cancer risks: what have we learned from epidemiology? Int J Radiat Biol. 2009;85(6):467-482.
24. Waller CF, Fetscher S, Lange W. Treatmentrelated chronic myelogenous leukemia. Ann Hematol. 1999;78(8):341-354.
25. Friedland W, Dingfelder M, Kundrat P, Jacob P. Track structures, DNA targets and radiation effects in the biophysical Monte Carlo simulation code PARTRAC. Mutat Res. 2011;711(1-2):28-40.
26. Grosswendt B, Pszona S, Bantsar A. New descriptors of radiation quality based on nanodosimetry, a first approach. Radiat Prot Dosimetry. 2007;126(1-4):432-444.
27. Hei TK, Ballas LK, Brenner DJ, Geard CR. Advances in radiobiological studies using a microbeam. J Radiat Res. 2009;50(suppl A): A7-A12.
28. Hodgson DC, Koh ES, Tran TH, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer. 2007;110(11):576-586.
29. Wardman P. The importance of radiation chemistry to radiation and free radical biology (The 2008 Silvanus Thompson Memorial Lecture). Br J Radiol. 2009;82(974):89-104.
30. Costes SV, Chiolo I, Pluth JM, Barcellos-Hoff MH, Jakob B. Spatiotemporal characterization of ionizing radiation induced DNA damage foci and their relation to chromatin organization. Mutat Res. 2010;704(1-3):78-87.
31. Sachs RK, Levy D, Hahnfeldt P, Hlatky L. Quantitative analysis of radiation-induced chromosome aberrations. Cytogenet Genome Res. 2004; 104(1-4):142-148. (Pubitemid 38721066)
32. Radivoyevitch T, Kozubek S, Sachs R. Biologically based risk estimation for radiation-induced CML: inferences from BCR and ABL geometric distributions. Radiat Environ Biophys. 2001;40: 1-9. (Pubitemid 32410997)
33. Nakachi K, Hayashi T, Hamatani K, Eguchi H, Kusunoki Y. Sixty years of follow-up of Hiroshima and Nagasaki survivors: current progress in molecular epidemiology studies. Mutat Res. 2008; 659(1-2):109-117.
34. Chaudhry MA. Biomarkers for human radiation exposure. J Biomed Sci. 2008;15(5):557-563.
35. NRC. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, DC: National Academy of Sciences; 2005.
36. Durante M, Cucinotta FA. Heavy ion carcinogenesis and human space exploration. Nat Rev Cancer. 2008;8(6):465-472. (Pubitemid 351744960)
37. Douple EB, Mabuchi K, Cullings HM, et al. Longterm radiation-related health effects in a unique human population: lessons learned from the atomic bomb survivors of Hiroshima and Nagasaki. Disaster Med Public Health Prep. 2011; 5(suppl 1):S122-S133.
38. Ozasa K, Shimizu Y, Sakata R, et al. Risk of cancer and non-cancer diseases in the atomic bomb survivors. Radiat Prot Dosimetry. 2011;146(1-3): 272-275.
39. Foo J, Drummond MW, Clarkson B, Holyoake T, Michor F. Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol. 2009;5(9):e1000503.
40. Manly BFJ. Randomization, Bootstrap, and Monte Carlo Methods in Biology (3rd Ed). Boca Raton, FL: Chapman & Hall/CRC, Taylor & Francis Group; 2006.
41. Tan W. Stochastic Models with Applications to Genetics, Cancers, AIDS, and Other Biomedical Systems. London, United Kingdom: World Scientific; 2002.
42. Wodarz D. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: implications for the outcome of imatinib treatment and discontinuation. Med Hypotheses. 2008; 70(1):128-136. (Pubitemid 350161156)
43. Michor F. Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells. 2007;25(5): 1114-1118. (Pubitemid 46684870)
44. Enderling H, Hlatky L, Hahnfeldt P. Migration rules: tumours are conglomerates of self-metastases. Br J Cancer. 2009;100(12):1917-1925.
45. Carlesso N, Cardoso AA. Stem cell regulatory niches and their role in normal and malignant hematopoiesis. Curr Opin Hematol. 2010;17(4): 281-286.
46. Nanda S, Moore H, Lenhart S. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math Biosci. 2007;210(1): 143-156. (Pubitemid 47562486)
47. UNSCEAR. Effects of Ionizing Radiation, Vol. I. Vienna, Austria: United Nations Scientific Committee on the Effects of Atomic Radiation; 2006.
48. Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res. 1994;137(2 suppl):S68-S97. (Pubitemid 24060247)
49. SEER. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-2008), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. SEER Web site. www.seer.cancer.gov. Released April 2011, based on the November 2010 submission.
50. Edwards AA, Szluinska M, Lloyd DC. Reconstruction of doses from ionizing radiation using fluorescence in situ hybridization techniques. Br J Radiol. 2007;80(spec no 1):S63-S67. (Pubitemid 47517801)
51. Sigurdson AJ, Ha M, Hauptmann M, et al. International study of factors affecting human chromosome translocations. Mutat Res. 2008;652(2): 112-121.
52. Tucker JD. Low-dose ionizing radiation and chromosome translocations: a review of the major considerations for human biological dosimetry. Mutat Res. 2008;659(3):211-220.
53. Ron E, Preston DL, Mabuchi K, Thompson DE, Soda M. Cancer incidence in atomic bomb survivors. Part IV. Comparison of cancer incidence and mortality. Radiat Res. 1994;137(2 suppl): S98-S112. (Pubitemid 24060248)
54. Sokal JE. Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment. Baillieres Clin Haematol. 1987;1(4):907-929.
55. Richardson D, Sugiyama H, Nishi N, et al. Ionizing radiation and leukemia mortality among Japanese atomic bomb survivors, 1950-2000. Radiat Res. 2009;172(3):368-382.
56. Ichimaru M, Ishimaru T, Mikami M, Yamada Y, Ohkita T. Incidence of Leukemia in a Fixed Cohort of Atomic Bomb Survivors and Controls, Hiroshima and Nagasaki, October 1950-December 1978. Hiroshima, Japan: RERF; 1981:13-81.
57. UNSCEAR. Sources and Effects of Ionizing Radiation. Vienna, Austria: United Nations Scientific Committee on the Effects of Atomic Radiation; 2008.
58. Pacheco JM, Traulsen A, Dingli D. The allometry of chronic myeloid leukemia. J Theor Biol. 2009; 259(3):635-640.
59. Catlin SN, Busque L, Gale RE, Guttorp P, Abkowitz JL. The replication rate of human hematopoietic stem cells in vivo. Blood. 2011;117(17): 4460-4466.
60. Wakeford R. Radiation in the workplace-a review of studies of the risks of occupational exposure to ionising radiation. J Radiol Prot. 2009;29(2A): A61-A79.
61. Little MP. Cancer and non-cancer effects in Japanese atomic bomb survivors. J Radiol Prot. 2009; 29(2A):A43-A59.
62. Inskip PD, Kleinerman RA, Stovall M, et al. Leukemia, lymphoma, and multiple myeloma after pelvic radiotherapy for benign disease. Radiat Res. 1993;135(1):108-124. (Pubitemid 23230673)
63. Howard RA, Gilbert ES, Chen BE, et al. Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat. 2007;105(3):359-368. (Pubitemid 47596449)
64. Nakamura N. A hypothesis: radiation-related leukemia is mainly attributable to the small number of people who carry pre-existing clonally expanded preleukemic cells. Radiat Res. 2005; 163(3):258-265. (Pubitemid 40293533)
65. Laukkanen MO, Kuramoto K, Calmels B, et al. Low-dose total body irradiation causes clonal fluctuation of primate hematopoietic stem and progenitor cells. Blood. 2005;105(3):1010-1015. (Pubitemid 40170869)
66. Little MP, Heidenreich WF, Moolgavkar SH, Schollnberger H, Thomas DC. Systems biological and mechanistic modelling of radiation-induced cancer. Radiat Environ Biophys. 2008;47(1):39-47.
67. Michor F, Iwasa Y, Nowak MA. The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proc Natl Acad Sci U S A. 2006;103(40):14931-14934. (Pubitemid 44527831)
68. Katouli AA, Komarova NL. Optimizing combination therapies with existing and future CML drugs. PLoS One. 2010;5(8):e12300.
69. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24(10):1719-1724.
70. Fakir H, Tan W, Hlatky L, Hahnfeldt P, Sachs R. Stochastic population dynamic effects for lung cancer progression. Radiat Res Suppl. 2009;172: 383-393.
71. Bauchinger M, Schmid E, Braselmann H. Timecourse of translocation and dicentric frequencies in a radiation accident case. Int J Radiat Biol. 2001;77(5):553-557. (Pubitemid 32436778)
72. Tucker JD. Chromosome translocations and assessing human exposure to adverse environmental agents. Environ Mol Mutagen. 2010;51 (8-9):815-824.
73. Radivoyevitch T, Ramsey MJ, Tucker JD. Estimation of the target stem-cell population size in chronic myeloid leukemogenesis. Radiat Environ Biophys. 1999;38(3):201-206. (Pubitemid 29483173)
74. Ramsey MJ, Moore DH 2nd, Briner JF, et al. The effects of age and lifestyle factors on the accumulation of cytogenetic damage as measured by chromosome painting. Mutat Res. 1995;338(1-6): 95-106.
75. Lucas JN. Translocation frequencies for low to moderate doses remain constant over time. Int J Radiat Biol. 1999;75(5):655-656. (Pubitemid 29243144)
76. Abkowitz JL, Catlin SN, McCallie MT, Guttorp P. Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. Blood. 2002;100(7):2665-2667.
77. Heidenreich WF, Luebeck EG, Hazelton WD, Paretzke HG, Moolgavkar SH. Multistage models and the incidence of cancer in the cohort of atomic bomb survivors. Radiat Res. 2002;158(5): 607-614. (Pubitemid 35266193)
78. Kellerer AM, Rossi HH. A generalized formulation of dual radiation action. Radiat Res. 1978;75:471-488. (Pubitemid 9002710)
79. Holmberg M. Is the primary event in radiationinduced chronic myelogenous leukemia the induction of the t(9;22) translocation? Leuk Res. 1992;16(4):333-336.
80. Radivoyevitch T, Hoel DG. Modeling the low-LET dose-response of BCR-ABL formation: predicting stem cell numbers from A-bomb data. Math Biosci. 1999;162(1-2):85-101.
81. Kozubek S, Lukasova E, Mareckova A, et al. The topological organization of chromosomes 9 and 22 in cell nuclei has a determinative role in the induction of t(9,22) translocations and in the pathogenesis of t(9,22) leukemias. Chromosoma. 1999;108(7):426-435. (Pubitemid 30028626)
82. Neves H, Ramos C, Silva MGD, Parreira A, Parreira L. The nuclear topography of ABL, BCR, PML, and RARalpha genes: evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation. Blood. 1999;93(4):1197-1207. (Pubitemid 29076134)
83. Harrison WJ. The total cellularity of the bone marrow in man. J Clin Pathol. 1962;15:254-259.
84. Berardi AC, Wang A, Levine JD, Lopez P, Scadden DT. Functional isolation and characterization of human hematopoietic stem cells. Science. 1995;267(5194):104-108.
85. Wang JC, Doedens M, Dick JE. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood. 1997;89(11):3919-3924. (Pubitemid 27220934)
86. Notta F, Doulatov S, Dick JE. Engraftment of human hematopoietic stem cells is more efficient in female NOD/SCID/IL-2Rgc-null recipients. Blood. 2010;115(18):3704-3707.
87. Radivoyevitch T, Kozubek S, Sachs RK. The risk of chronic myeloid leukemia: can the doseresponse curve be U-shaped? Radiat Res. 2002; 157(1):106-109. (Pubitemid 34073394)
88. Radivoyevitch T, Hoel DG. Biologically-based risk estimation for radiation-induced chronic myeloid leukemia. Radiat Environ Biophys. 2000;39(3): 153-159.
89. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011; 117(14):3733-3736.
90. Pawliuk R, Eaves C, Humphries RK. Evidence of both ontogeny and transplant dose-regulated expansion of hematopoietic stem cells in vivo. Blood. 1996;88(8):2852-2858. (Pubitemid 26357365)
91. Roberts AW, DeLuca E, Begley CG, Basser R, Grigg AP, Metcalf D. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells. 1995;13(5):512-516.
92. Selleri C, Maciejewski JP, De Rosa G, et al. Longlasting decrease of marrow and circulating longterm culture initiating cells after allogeneic bone marrow transplant. Bone Marrow Transplant. 1999;23(10):1029-1037. (Pubitemid 29250848)
93. Podesta M, Piaggio G, Frassoni F, et al. The assessment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia. Blood. 1998;91(6):1959-1965. (Pubitemid 28185496)
94. Mesarovic MD, Sreenath SN, Keene JD. Search for organising principles: understanding in systems biology. Syst Biol. 2004;1(1):19-27.
95. Komarova NL, Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A. 2005;102(27):9714-9719. (Pubitemid 40981746)
96. Dingli D, Traulsen A, Lenaerts T, Pacheco JM. Evolutionary dynamics of chronic myeloid leukemia. Genes Cancer. 2010;1(4):309-315.
97. Vickers M. Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data. Br J Haematol. 1996; 94(1):1-4. (Pubitemid 26232532)
98. Moolgavkar SH, Luebeck EG. Multistage carcinogenesis and the incidence of human cancer. Genes Chromosomes Cancer. 2003;38(4):302-306. (Pubitemid 37466929)
99. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Int J Epidemiol. 2004;33(6):1174-1179. (Pubitemid 40124910)
100. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7(4):233-245. (Pubitemid 46480968)